Optimi Completes Psilocybin Batch for Phase 2 MDD Trial and Australian Supply
OPTH sits 27% above its 52-week low of $4.
Summary
Optimi Health has completed and quality-released a production batch of 5mg psilocybin capsules that will supply both its Health Canada-approved Phase 2 MDD trial and commercial customers in Australia. The trial is multisite, open-label, with up to 200 participants, and dosing is expected to finish by end of 2027. This follows the September 10 announcement of the trial authorization and the June 29 third commercial export to Australia. The dual-use batch demonstrates manufacturing capability and regulatory compliance, but no new revenue or trial data is provided. Watch for patient enrollment updates and any interim safety data from the trial.
At the time of this announcement, OPTH was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.4M. The 52-week trading range was $4.00 to $8.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.